Skip to main content

Table 2 Estimated treatment effect for each outcome relative to fluconazole (base case analysis using a non-informed prior)

From: Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

Comparator Median posterior odds-ratio relative to fluconazole
(interquartile range)a
Posterior probability of having lower incidence than fluconazole Posterior probability of having the lowest incidence of all treatments
Proven/probable IFI at 180 days
Fluconazole 2%
Itraconazole 0.52 (0.35–0.76) 84% 27%
Posaconazole 0.56 (0.32–0.99) 75% 32%
Voriconazole 0.46 (0.28–0.73) 84% 39%
Proven/probable IA at 180 days
Fluconazole 2%
Itraconazole 0.68 (0.42–1.12) 71% 9%
Posaconazole 0.31 (0.15–0.63) 83% 47%
Voriconazole 0.33 (0.17–0.58) 87% 41%
Proven IC at 180 days
Fluconazole 5%
Itraconazole 0.28 (0.11– 0.60) 85% 59%
Posaconazole 0.98 (0.28–3.45) 51% 23%
Voriconazole 1.19 (0.43–4.19) 46% 13%
All-cause mortality
Fluconazole 20%
Itraconazole 1.18 (0.96–1.44) 29% 11%
Posaconazole 0.98 (0.74–1.27) 53% 40%
Voriconazole 1.02 (0.82–1.26) 48% 29%
OLAT use at 180 days
Fluconazole 10%
Itraconazole 0.91 (0.49–1.58) 56% 18%
Posaconazole 1.08 (0.53–2.21) 46% 23%
Voriconazole 0.63 (0.35–1.09) 73% 49%
  1. IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT, other licensed antifungal therapy.
  2. aEstimates less than zero indicate a reduced probability of proven/probable IFI at 180 days relative to fluconazole.